NuCana Beheer
Beheer criteriumcontroles 3/4
De CEO NuCana is Hugh Griffith, benoemd in Mar2008, heeft een ambtstermijn van 16.67 jaar. De totale jaarlijkse vergoeding van { bedraagt £ 974.59K, bestaande uit 58.9% salaris en 41.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.25% van de aandelen van het bedrijf, ter waarde $ 62.24K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.1 jaar en 6.5 jaar.
Belangrijke informatie
Hugh Griffith
Algemeen directeur
UK£974.6k
Totale compensatie
| Percentage CEO-salaris | 58.9% |
| Dienstverband CEO | 16.7yrs |
| Eigendom CEO | 2.3% |
| Management gemiddelde ambtstermijn | 4.1yrs |
| Gemiddelde ambtstermijn bestuur | 6.5yrs |
Recente managementupdates
Recent updates
Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?
Aug 21
Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely
Mar 14We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate
Oct 15Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation
Jul 01Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
Mar 15Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
Nov 30NuCana: An Intriguing 'Sum Of The Parts' Story
Sep 22NuCana GAAP EPS of -£0.07
Aug 17NuCana regains Nasdaq compliance
Jul 27NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead
Jul 13Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
May 02We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth
Jan 17NuCana: Preparing For A Critical 2022
Dec 08We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow
Sep 30NuCana: The Market Continues To Overlook Its ProTide Platform Technology
Sep 11We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth
Jun 01Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth
Feb 15How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?
Dec 22
NuCana (NCNA) Investor Presentation - Slideshow
Dec 02NuCana reports Q3 results
Nov 19Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -UK£28m |
| Mar 31 2024 | n/a | n/a | -UK£27m |
| Dec 31 2023 | UK£975k | UK£574k | -UK£28m |
| Sep 30 2023 | n/a | n/a | -UK£35m |
| Jun 30 2023 | n/a | n/a | -UK£33m |
| Mar 31 2023 | n/a | n/a | -UK£31m |
| Dec 31 2022 | UK£1m | UK£552k | -UK£32m |
| Sep 30 2022 | n/a | n/a | -UK£30m |
| Jun 30 2022 | n/a | n/a | -UK£34m |
| Mar 31 2022 | n/a | n/a | -UK£39m |
| Dec 31 2021 | UK£907k | UK£531k | -UK£41m |
| Sep 30 2021 | n/a | n/a | -UK£39m |
| Jun 30 2021 | n/a | n/a | -UK£40m |
| Mar 31 2021 | n/a | n/a | -UK£36m |
| Dec 31 2020 | UK£920k | UK£551k | -UK£31m |
| Sep 30 2020 | n/a | n/a | -UK£26m |
| Jun 30 2020 | n/a | n/a | -UK£22m |
| Mar 31 2020 | n/a | n/a | -UK£20m |
| Dec 31 2019 | UK£828k | UK£498k | -UK£21m |
| Sep 30 2019 | n/a | n/a | -UK£17m |
| Jun 30 2019 | n/a | n/a | -UK£16m |
| Mar 31 2019 | n/a | n/a | -UK£13m |
| Dec 31 2018 | UK£786k | UK£467k | -UK£14m |
| Sep 30 2018 | n/a | n/a | -UK£15m |
| Jun 30 2018 | n/a | n/a | -UK£26m |
| Mar 31 2018 | n/a | n/a | -UK£28m |
| Dec 31 2017 | UK£635k | UK£330k | -UK£23m |
Compensatie versus markt: De totale vergoeding ($USD 1.22M ) Hugh } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.63K ).
Compensatie versus inkomsten: De vergoeding van Hugh is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Hugh Griffith (56 yo)
16.7yrs
Tenure
UK£974,586
Compensatie
Mr. Hugh Stephen Griffith is Founder of NuCana plc (formerly, NuCana BioMed Limited) and has been its Chief Executive Officer since March 2008. Mr. Griffith was also the Chief Executive Officer at Alida Ca...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 16.7yrs | UK£974.59k | 2.25% $ 62.2k | |
| Chief Financial Officer | 9.1yrs | geen gegevens | 0.28% $ 7.6k | |
| Head of Translational Medicine | 6.9yrs | geen gegevens | 0% $ 0 | |
| Chief Medical Officer | 3.3yrs | geen gegevens | 0.00018% $ 5.0 | |
| Senior Vice President of Clinical Operations | 4.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Medical & Clinical Development | 4.1yrs | geen gegevens | geen gegevens | |
| Senior VP of Strategy & Lifecycle Management | less than a year | geen gegevens | geen gegevens | |
| Senior VP of CMC & Development | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of Regulatory Affairs | less than a year | geen gegevens | geen gegevens | |
| Company Secretary | no data | geen gegevens | geen gegevens |
4.1yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van NCNA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 16.7yrs | UK£974.59k | 2.25% $ 62.2k | |
| Independent Non-Executive Chairman | 3.9yrs | UK£78.77k | 0% $ 0 | |
| Independent Non-Executive Director | 14.9yrs | UK£47.85k | 0.050% $ 1.4k | |
| Independent Non Executive Director | 6.6yrs | UK£56.56k | 0% $ 0 | |
| Independent Non-Executive Director | 4.2yrs | UK£29.25k | 0.00098% $ 27.1 | |
| Independent Director | 3yrs | UK£54.23k | 0.0084% $ 231.3 | |
| Independent Non Executive Director | 6.5yrs | UK£65.08k | 0% $ 0 |
6.5yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van NCNA wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.5 jaar).